词条 | National Intelligence Assessments on Infectious Diseases |
释义 |
The United States intelligence community (IC) has a long history of producing assessments on infectious diseases. Most of these papers are distributed to government administrators and inform the choices of policymakers. Three of these assessments stand out as analytical products that have had important impact on the awareness, funding and treatment of infectious diseases around the world. The first paper is the National Intelligence Estimate on the Global Infectious Disease Threat,[1] the second paper is the assessment on the Next Wave of HIV/AIDS,[2] and the third paper was the assessment on SARS.[3] This page summarizes the findings of these three papers and provides information about their impact. National Intelligence Estimate on the Global Infectious Disease ThreatIn January, 2000, The National Intelligence Council released its National Intelligence Estimate on the Global Infectious Disease Threat. This paper examined the re-emergence of the threat from infectious diseases worldwide and its implications for the United States. It stated that infectious diseases were a leading cause of death, accounting for a quarter to a third of the estimated 54 million deaths worldwide in 1998, and that the spread of infectious diseases results as much from changes in human behavior—including lifestyles and land use patterns, increased trade and travel, and inappropriate use of antibiotic drugs—as from mutations in pathogens.[1] Additionally, the paper found that new and reemerging infectious diseases will pose a rising global health threat and will complicate US and global security over the next 20 years. These diseases will endanger US citizens at home and abroad, threaten US armed forces deployed overseas, and exacerbate social and political instability in key countries and regions in which the United States has significant interests.
Regional trendsDeveloping countries will continue to experience the greatest impact from infectious diseases—because of malnutrition, poor sanitation, poor water quality, and inadequate health care—but developed countries also will be affected.[1] Impact within the United StatesAlthough the infectious disease threat in the United States remains relatively modest as compared to that of noninfectious diseases, the trend is up. Annual infectious disease-related death rates in the United States have nearly doubled to some 170,000 annually after reaching an historic low in 1980.[4] Many infectious diseases—most recently, the West Nile virus—originate outside U.S. borders and are introduced by international travelers, immigrants, returning U.S. military personnel, or imported animals and foodstuffs. In the opinion of the U.S. Institute of Medicine, the next major infectious disease threat to the United States may be, like HIV, a previously unrecognized pathogen. Barring that, the most dangerous known infectious diseases likely to threaten the United States over the next two decades will be HIV/AIDS, hepatitis C, tuberculosis, and new, more lethal variants of influenza. Hospital-acquired infections[5] and foodborne illnesses also will pose a threat.[1]
Sub-Saharan Africa65% of all deaths in Sub-Saharan Africa come from infectious diseases. Rudimentary health care delivery and response systems, the unavailability or misuse of drugs, the lack of funds, and the multiplicity of conflicts are exacerbating the crisis. Investment in health care in the region is minimal, less than 40 percent of the people in countries such as Nigeria and the Democratic Republic of the Congo (DRC) have access to basic medical care, and even in relatively well off South Africa, only 50–70% have such access, with black populations at the low end of the spectrum. It will remain the most vulnerable region. The death rates for many diseases, including HIV/AIDS and malaria, exceed those in all other regions. Sub-Saharan Africa's health care capacity—the poorest in the world—will continue to lag. Sub-Saharan Africa also has an estimated 90 percent of the global malaria burden. Cholera, dysentery, and other diarrheal diseases also are major killers in the region, particularly among children, refugees, and internally displaced populations. Forty percent of all childhood deaths from diarrheal diseases occur in Sub-Saharan Africa. The region also has a high rate of hepatitis B and C infections and is the only region with a perennial meningococcal meningitis problem in a "meningitis belt" stretching from west to east.[1][6] Sub-Saharan Africa also suffers from yellow fever, while trypanosomiasis or "sleeping sickness" is making a comeback in the DROC and Sudan, and the Marburg virus also appeared in DRC for the first time in 1998. Ebola hemorrhagic fever strikes sporadically in countries such as the DRC, Gabon, Cote d'Ivoire, and Sudan. Asia and the PacificMultidrug resistant TB, malaria, and cholera are rampant in this area. The spread of HIV/AIDS, with its immunosuppression, will lead to a dramatic increase in infectious disease deaths. By 2010, the region could surpass Africa in the number of HIV infections.[1] Although the more developed countries of Asia and the Pacific, such as Japan, South Korea, Australia, and New Zealand, have strong records in combating infectious diseases, infectious disease prevalence in South and Southeast Asia is almost as high as in Sub-Saharan Africa. The health care delivery system of the Asia and Pacific region—the majority of which is privately financed—is particularly vulnerable to economic downturns even though this is offset to some degree by much of the region's reliance on traditional medicine from local practitioners. In South and Southeast Asia, reemergent diseases such as TB, malaria, cholera, and dengue fever are rampant, while HIV/AIDS, after a late start, is growing faster than in any other region. TB caused 1 million deaths in the Asia and Pacific region in 1998, more than any other single disease, with India and China accounting for two-thirds of the total.[1] Several million new cases occur annually—most in India, China and Indonesia—representing as much as 40 percent of the global TB burden. HIV/AIDS is increasing dramatically, especially in India, which leads the world in absolute numbers of HIV/AIDS infections, estimated at 3–5 million. China is better off than most of the countries to its south, but it too has a growing AIDS problem, with HIV infections variously estimated at 100,000 to 4000,000. and spreading rapidly. Regionwide, the number of people infected with HIV could overtake Sub-Saharan Africa in absolute numbers before 2010. Former Soviet Union (FSU) and Eastern EuropeThese areas will see a substantial increase in infectious disease incidence and deaths. In the FSU especially, the steep deterioration in health care and other services owing to economic decline has led to a sharp rise in diphtheria, dysentery, cholera, and hepatitis B and C. TB has reached epidemic proportions throughout the FSU, while the HIV-infected population in Russia alone could exceed 1 million by the end of 2000 and double yet again by 2002.[7] The sharp decline in health care infrastructure in Russia and elsewhere in the former Soviet Union (FSU) and, to a lesser extent, in Eastern Europe—owing to economic difficulties—are causing a dramatic rise in infectious disease incidence. Death rates attributed to infectious diseases in the FSU increased 50% from 1990 to 1996, with TB accounting for a substantial number of such deaths. Access to health care ranges from 50–70% in most European FSU states, including Russia and Ukraine, and from 40–50% in FSU states located in Central Asia. WHO estimates are consistent, that only 50–80% of FSU citizens had regular access to essential drugs in 1997, as compared to more than 95% a decade earlier as health care budgets and government-provided health services were slashed.[7] Health care access is better in Eastern Europe, particularly in more developed states such as Poland, the Czech Republic, and Hungary, where it ranges from 70 to 90%, while only 50-70% have access in countries such as Bulgaria and Romania. More than 95 percent of the population throughout the East European region had such access in 1987, according to WHO. Crowded living conditions are among the causes fueling a TB epidemic in the FSU, especially among prison populations—while surging intravenous drug abuse (IVDA) and rampant prostitution are substantially responsible for a marked increase in HIV/AIDS incidence. There were 111,000 new TB infections and 25,000 deaths in Russia alone in 1996, a growing number of them multidrug resistant. The number of new infections for the entire FSU in 1996 was 188,000, while East European cases totaled 54,000. Diphtheria reached epidemic proportions in the FSU in the first half of the decade, owing to lapses in vaccination. Cholera and dysentery outbreaks are occurring with increasing frequency in Russian cities, such as St. Petersburg and Moscow, and elsewhere in the FSU, such as in Tbilisi, owing to deteriorating water treatment and sewerage systems. Hepatitis B and C, spread primarily by IVDA and blood transfusions, are on the rise, especially in the non-European part of the FSU. Polio also has reappeared owing to interruptions in vaccination, with 140 new cases in Russia in 1995.[7]Latin AmericaThere is distinct progress in infectious disease control in this region, including the eradication of polio, but uneven economic development has contributed to widespread resurgence of cholera, malaria, TB, and dengue. These diseases will continue to take a heavy toll in tropical and poorer countries.[8] Latin American countries are making considerable progress in infectious disease control, including the eradication of polio and major reductions in the incidence and death rates of measles, neonatal tetanus, some diarrheal diseases, and acute respiratory infections. Nonetheless, infectious diseases are still a major cause of illness and death in the region, and the risk of new and reemerging diseases remains substantial.[8][9] Widening income disparities, periodic economic shocks, and rampant urbanization have disrupted disease control efforts and contributed to widespread reemergence of cholera, malaria, TB, and dengue, especially in the poorer Central American and Caribbean countries and in the Amazon basin of South America. According to the AFMIC typology, Latin America's health care capacity is substantially more advanced than that of Sub-Saharan Africa and somewhat better than mainland Asia's, with 70–90% of populations having access to basic health care in Chile, Costa Rica, and Cuba on the upper end of the scale. Less than 50 percent have such access in Haiti, most of Central America, and the Amazon basin countries, including the rural populations in Brazil.[8] Cholera reemerged with a vengeance in the region in 1991 for the first time in a century with 400,000 new cases, and while dropping to 100,000 cases in 1997, it still comprises two-thirds of the global cholera burden.[8] TB is a growing problem regionwide, especially in Brazil, Peru, Argentina, and the Dominican Republic where drug-resistant cases also are on the rise. Haiti does not provide data but probably also has a high infection rate. HIV/AIDS also is spreading rapidly, placing Latin America third behind Sub-Saharan Africa and Asia in HIV prevalence. Prevalence is high in Brazil and especially in the Caribbean countries (except Cuba), where 2 percent of the population is infected. Malaria is prevalent in the Amazon basin. Dengue reemerged in the region in 1976, presenting both as the usual form and the more lethal dengue hemorrhagic fever (DHF). Hepatitis B and C prevalence is greatest in the Amazon basin, Bolivia, and Central America, while DHF is particularly prevalent in Brazil, Colombia,[8] and Venezuela. Yellow fever has made a comeback over the last decade throughout the Amazon basin, and there have been several recent outbreaks of gastrointestinal disease attributed to E. coli infection in Chile, Argentina, Bolivia and Peru[10] Hemorrhagic fevers are present in almost all South American countries, and most hantavirus pulmonary syndrome occurs in the southern cone. The Middle East and North Africa regionhas substantial TB and hepatitis B and C prevalence, but conservative social mores, climatic factors, and the high level of health spending in the oil-producing states tend to limit some globally prevalent diseases, such as HIV/AIDS and malaria. The region has the lowest HIV infection rate among all regions, although this is probably due in part to above-average underreporting because of the stigma associated with the disease in Muslim societies.[11] The region's conservative social mores, climatic factors, and high levels of health spending in oil-producing states tend to limit some globally prevalent diseases, such as HIV/AIDS and malaria, but others, such as TB and hepatitis B and C, are more prevalent. The region's advantages are partially offset by the impact of war-related uprooting of populations, overcrowded cities with poor refrigeration and sanitation systems, and a dearth of water, especially clean drinking water. Health care capacity varies considerably within the region, according to the AFMIC typology. Israel and the Arabian Peninsula states minus Yemen are in far better shape than Iraq, Iran, Syria, and most of North Africa. Ninety to 100 percent of the Israeli population and 70 to 90 percent of the Saudi population have good access to health care. Elsewhere, access ranges from less than 40 percent in Yemen to 50 to 70 percent in the smaller Gulf states, Jordan and Tunisia, while most North African states fall into the 40- to-50-percent category.[11] Western EuropeThreats from several infectious diseases, include both those transmitted by humans, such as HIV/AIDS, TB, and Hepatitis B and C, as well as from several economically costly zoonotic diseases (that is, those transmitted from animals to humans). The region's large volume of travel, trade, and immigration increases the risks of importing diseases from other regions, but its highly developed health care systems will limit their impact.[12] Its status as a hub of international travel, commerce, and immigration, moreover, dramatically increases the risks of importing new diseases from other regions. Tens of millions of West Europeans travel to developing countries annually, increasing the prospects for the importation of dangerous diseases, as demonstrated by the importation of Typhoid in 1999. Some 88 percent of the regional population growth in the first half of the decade was due to immigration; legal immigrants now comprise about 6 percent of the population, and illegal newcomers number an estimated 6 million. Nonetheless, the region's highly developed health care infrastructure and delivery system tend to limit the incidence and especially the death rates of most infectious diseases, though not the economic costs. Access to high-quality care is available throughout most of the region, although governments are beginning to limit some heretofore generous health benefits, and a growing antivaccination movement in parts of Western Europe, such as Germany, is causing a rise in measles and other vaccine-preventable diseases.[12] The AFMIC typology gives somewhat higher marks to northern over some southern European countries, but the region as a whole is ranked in the highest category, along with North America. TB, especially its multidrug resistant strains, is on the upswing,[13] as is co-infection with HIV, particularly in the larger countries, with some 50,000 TB cases reported in 1996.[12] Hepatitis C prevalence is growing, especially in southern Europe. Western Europe also continues to suffer from several zoonotic diseases, among which is the deadly new variant Creutzfeldt–Jakob disease (nvCJD), linked to the bovine spongiform encephalopathy or "mad cow disease" outbreak in the United Kingdom in 1995 that has since ebbed following implementation of strict control measures. Other recent disease concerns include meningococcal Meningitis outbreaks in the Benelux countries and leishmaniasis-HIV co-infection, especially in southern Europe. Response capacityDevelopment of an effective global surveillance and response system probably is at least a decade or more away, owing to inadequate coordination and funding at the international level and lack of capacity, funds, and commitment in many developing and former communist states. Although overall global health care capacity has improved substantially in recent decades, the gap between rich and poorer countries in the availability and quality of health care. In most poorer countries, health care—ranging from basic pharmaceuticals and postnatal care to costly multidrug therapies—remains very limited. Market forces drive private pharmaceutical companies, and many developed country government research programs, to focus on drugs needed in their environment, not necessarily those of the poorer countries. This is generating a growing controversy between rich and poorer nations over such issues as intellectual property rights, as some developing countries make their own copies, not always with permission, of drugs under patent protection.[14][15] Developing countries also are less willing to make microbial samples available to companies that will make commercial vaccines from them, which may be too costly for the country that provided the sample.[16] A global composite measure of health care infrastructure devised by DIA's Armed Forces Medical Intelligence Center (AFMIC) assesses factors such as the priority attributed to health care, health expenditures, the quality of health care delivery and access to drugs, and the extent of surveillance and response systems. A major obstacle to effective global surveillance and control of infectious diseases will continue to be the quality of national health statistical reporting by many developing countries and lack of followthrough to properly direct aid and to follow recommended health care practices.[14] Those areas of the world most susceptible to infectious disease problems are least able to develop and maintain the sophisticated and costly communications equipment needed for effective disease surveillance and reporting. In addition to the barriers dictated by low levels of development, revealing a disease outbreakmay harm national prestige, commerce, and tourism. For example, nearly every country initially denied or minimized the extent of the HIV/AIDS virus within its borders, and even today, some countries known to have significant rates of HIV infection refuse to cooperate with WHO. Only a few, such as Uganda, Senegal, and Thailand, have launched major preventative efforts, while many WHO members do not even endorse AIDS education in schools. Similarly, some countries deny the existence of cholera within their borders.[14] Aid programs to prevent and treat infectious diseases in developing countries depend largely on indigenous health workers for their success and cannot be fielded effectively in their absence. Training indigenous workers appears more effective than educating the general public of these countries. International organizations such as WHO and the World Bank, institutions in several developed countries such as the U.S. Centers for Disease Control and Prevention, and Nongovernmental Organizations (NGOs) will continue to play an important role in strengthening both international and national surveillance and response systems for infectious diseases. Development of an integrated global surveillance and response system probably is at least a decade or more away. This owes to the magnitude of the challenge; inadequate coordination at the international level; and lack of funds, capacity, and, in some cases, cooperation and commitment at the national level. Some countries hide or understate their infectious disease problems for reasons of prestige and fear of economic losses. Total international health-related aid to low- and middle-income countries—some $2–3 billion annually—remains a fraction of the $250 billion health bill of these countries. WHO has the broadest health mandate under the UN system, including setting priorities, coordinating global health surveillance, and emergency assistance in the event of disease outbreaks. Health experts give WHO credit for major successes, such as the eradication of smallpox, near eradication of polio, and substantial progress in controlling childhood diseases, and in expanding primary health care in developing countries. WHO defenders blame continued member state parsimony that has kept WHO's regular biennial budget to roughly $850 million for several years and forced it to rely more on voluntary contributions that often come with strings attached as the cause of its shortcomings. This situation led to lack of focus at the top level as well as overly optimistic forecasts. The 1998 election of Gro Harlem Brundtland as Secretary General, along with a series of reforms, including expansion of the Emerging and other Communicable Diseases Surveillance and Control (EMC) Division, has placed WHO in a better position to revitalize itself. Internal oversight and transparency have been expanded, programs and budgets are undergoing closer scrutiny, and management accountability is looming larger. Bruntland has moved quickly to revitalize top management, mostly from outside the organization, including from the private sector. She also strengthened country offices and to make the regional offices more responsive to central direction. WHO is increasing its focus on the fight against resurgent malaria, while a better-funded EMC is expanding efforts to establish a global surveillance and response system in cooperation with UNAIDS, UNICEF, and national entities such as the U.S. CDC, the U.S. DoD, and France's Pasteur Institute. Margaret Chan, the current Director-General, is still being assessed; there were questions about her performance as chief of public health for Hong Kong. WHO competes for resources with other UN agencies that are involved in health care. The United Nations Children's Fund (UNICEF) focuses on children's health. The United Nations AIDS Program (UNAIDS) focuses on improving the response capacity toward HIV/AIDS at the country, regional, and global levels in cooperation with other UN agencies. Other UN agencies involved in health care issues include the UN Development Program (UNDP); the UN Family Planning Agency (UNFPA); the UN High Commissioner for Refugees (UNHCR); the UN Educational, Scientific and Cultural Organization (UNESCO); the International Labor Organization (ILO); the Food and Agricultural Organization (FAO); and the World Food Program (WFP). Alternative scenariosThe 1999 estimate[17] looked at three plausible scenarios for the course of the infectious disease threat over the next 20 years:
Economic, social, and political impactThe persistent infectious disease burden is likely to aggravate and, in some cases, may even provoke economic decay, social fragmentation, and political destabilization in the hardest hit countries in the developing and former communist worlds, especially in the worst-case scenario outlined above:[19]
The relationship between disease and political instability is indirect but real. A wide-ranging study on the causes of state instability suggests that infant mortality—a good indicator of the overall quality of life—correlates strongly with political instability, particularly in countries that already have achieved a measure of democracy. The severe social and economic impact of infectious diseases is likely to intensify the struggle for political power to control scarce state resources. As a major hub of global travel, immigration, and commerce with wide-ranging interests and a large civilian and military presence overseas, the United States and its equities abroad will remain at risk from infectious diseases.
Intelligence Community Assessment on the Next Wave of HIV/AIDSIn July, 2002, The National Intelligence Council released the Intelligence Community Assessment on the Next Wave of HIV/AIDS. This paper examined HIV epidemics in five countries of strategic importance to the United States that have large populations at risk for HIV infection: Nigeria, Ethiopia, Russia, India, and China. The five countries were selected because they were:
The paper concluded that HIV/AIDS is spreading at different rates in the five countries, with the epidemic the most advanced in Nigeria and Ethiopia. In all countries, however, risky sexual behaviors are driving infection rates upward at a precipitous rate.
It will be difficult for any of the five countries to check their epidemics by 2010 without dramatic shifts in priorities. The disease has built up significant momentum, health services are inadequate, and the cost of education and treatment programs will be overwhelming. Government leaders will have trouble maintaining a priority on HIV/AIDS—which has been key to stemming the disease in Uganda, Thailand, and Brazil—because of other pressing issues and the lack of AIDS advocacy groups.
The rise of HIV/AIDS in the next-wave countries is likely to have significant economic, social, political, and military implications. The impact will vary substantially among the five countries, however, because of differences among them in the development of the disease, likely government responses, available resources, and demographic profiles.
The growing AIDS problem in the next-wave countries probably will spark calls for more financial and technical support from donor countries. It may lead to growing tensions over how to disburse international funds, such as the Global Fund for AIDS, TB and Malaria. The cost of antiretroviral drugs—which can prolong the lives of infected people—has plunged in recent years but still may be prohibitively high for low-income countries. More importantly, the drug costs are only a portion of HIV/AIDS treatment costs. Drug-resistant strains are likely to spread because of the inconsistent use of antiretroviral therapies and the manufacture overseas of unregulated, substandard drugs.
According to UNAIDS, Asia alone is likely to outstrip Sub-Saharan Africa in the absolute number of HIV carriers by 2010. Governments often do not spend enough money to get quality infection surveillance because they have other budget priorities, do not want to acknowledge the extent of the epidemic, and the drug users and prostitutes at high risk of infection are not key political constituencies.
infections.
Even if testing is available, many people do not get tested because of denial, stigma, discrimination, or resignation.
NigeriaHeterosexual transmission of HIV is the primary mode of spread in Nigeria, and infections appear to be as numerous in rural areas as in the cities. In other words, HIV is endemic in the general population. The reported rate of infection apparently varies significantly by region, with the lowest reported rate found generally in the predominantly Muslim northern parts of the country. Infections are most numerous among men ages 20 through 24, but some experts caution that infection rates are rising quickly in young women. Given the already advanced state of the disease and the government’s limited capacity to respond, the Intelligence Community expects HIV/AIDS to infect as many as 10 to 15 million people by 2010. Nigerian prevalence may be 18 to 26 percent of adults—close to the current rates in some of the hardest hit countries in southern Africa. This graphic is of a second-wave country; Southern Africa is already badly affected by the first wave. EthiopiaEthiopia is estimated to have the highest adult prevalence rate, between 10 and 18%—was the highest among the five countries. This reflects two social effects:
The figure to the right shows prevalence at prenatal clinics, which appears to be the best single indicator. Expert estimates the actual number of HIV patients may be between 3 and 5 million. Adult prevalence is much higher in cities (13–20%) than in rural areas (5%). Heterosexual transmission is the primary mode of spread, and people with multiple partners—especially those with sexually transmitted diseases (STDs) and prostitutes—have significantly higher infection rates. Unlike conditions in other next-wave countries, war has significantly contributed to the spread of the disease in Ethiopia. Many soldiers contracted HIV/AIDS during the civil war in the 1980s by having contact with multiple sex partners. When the war ended in 1991, thousands of infected soldiers and prostitutes returned home, spreading HIV/AIDS in their villages and towns. Ethiopians, due to result of drought, malnutrition, limited healthcare, and other infectious diseases, have generally poor health. In the HIV-seropositive group, this has caused HIV to progress rapidly to AIDS. Looking ahead, we expect 7 to 10 million Ethiopians probably will be infected by 2010 because of the high current rate of adult prevalence, widespread poverty, low educational levels, and the government’s limited capacity to respond more actively. RussiaEach country in the second wave have different social factors causing increased spread.[7] HIV has not yet made a move into the general populations of some countries, such as Russia. The single social factor (80–90% of new cases) for Russian spread is IVDA, coming from prostitutes and prison inmates—many of whom are IVDAs—are contributing to the spread of the disease. Drug use is so widespread that many users are integrated into society with jobs and families, suggesting the disease is moving into the mainstream. An estimated 20–25% of IVDA in prison, where there is easy access to drugs, are seropositive.[7] HIV/AIDS also is increasing in the Russian military services. Up to 33% of prospective conscripts are deemed unfit for service owing to the effects of prior drug use (chronic hepatitis or HIV infection).[7] Enlisted men in the ground troops have the largest number of infections, while strategic military forces and airborne troops have the lowest. IndiaChinaIntelligence Community Assessment on Severe Acute Respiratory SyndromeThe outbreak of Severe Acute Respiratory Syndrome (SARS) has been overcome, but SARS has not been eradicated. Although WHO declared on 5 July 2003 that all transmission chains of SARS had been broken, many health experts fear it could return again. We remain vulnerable. The major concerns include:
The emergence of SARS illustrates the challenge of battling infectious diseases in an increasingly globalized world. Global links have sped the geographic spread of the disease and amplified the economic and political impact. The initial SARS outbreakSARS exemplifies the potential of an infection spread through air travel. The first case of SARS was reportedly originated from a rural area in Foshan, Guangdong, in Nov 2002, and the patient, a farmer, was treated in the First People's Hospital of Foshan. The patient died soon after, and no definite diagnosis was made on his cause of death. China delayed reporting this to international health organizations, and SARS spread beyond China.[1][20] Outside China, the first clue of the outbreak appears to be November 27, 2002 when Canada's Global Public Health Intelligence Network (GPHIN), an electronic warning system that is part of the World Health Organization's (WHO) Global Outbreak and Alert Response Network (GOARN), picked up reports of a "flu outbreak" in China through internet media monitoring and analysis and sent them to the WHO.[21][22] Subsequently, the WHO requested information from Chinese authorities on December 5 and 11.[23] Importantly, while GPHIN's capability had recently been upgraded to enable Arabic, Chinese, English, French, Russian and Spanish translation, the system was limited to English or French in presenting this information. Thus, while the first reports of an unusual outbreak were in Chinese, an English report was not generated until January 21, 2003.[24] In late April, revelations occurred as the PRC government admitted to underreporting the number of cases of SARS due to the problems inherent in the healthcare system. Dr. Jiang Yanyong exposed the coverup that was occurring in China, at great personal risk. A number of PRC officials were fired from their posts, including the health minister and mayor of Beijing, and systems were set up to improve reporting and control in the SARS crisis. Since then, the PRC has taken a much more active and transparent role in combating the SARS epidemic. Potential of SARS recurrencePolitical leadership has been a key variable in managing the epidemic. China’s efforts to hide the initial outbreak allowed SARS to build up dangerous momentum before Chinese officials became more open, while Vietnam’s willingness to promptly highlight the threat and seek international assistance helped offset the country’s weak healthcare system. The more SARS spread, the tougher countries became in implementing control measures, including quarantining and isolating people to stop its transmission.[25]
The intense focus on SARS has opened a window of opportunity for the United States and the WHO to pursue longer-term bilateral and multilateral cooperation on health issues. Three scenarios for SARSThe future course of SARS will depend on a host of complex variables, making forecasting difficult. Complexity and uncertainty preclude assessing the relative likelihood of any one of the three. SARS, even in a developed country, demands extremely careful nursing practices to avoid having the disease spread by medical personnel, according to WHO.[26] Countries that lack the necessary respirators and other barrier nursing equipment can risk spread. The first scenarion is "SARS Simmers": SARS could resurface but be limited to random outbreaks in a few countries, rendering it more of a public health nuisance than a crisis. Political and economic reverberations still would occur, with some companies and investors looking to reduce their exposure in East Asia, particularly China. The next alternative is that "SARS Gains a Foothold in Poor Countries, Regions. SARS could spread to poor countries in Africa or Asia, potentially generating more infections and deaths than before but with relatively little international economic impact. The risk of spread would continue, however, even if SARS emerged in poor countries or isolated regions of Russia and China with weak healthcare systems. WHO and CDC probably would come under intense pressure to provide money and technical assistance to compensate for weak healthcare systems. Some isolated countries such as North Korea probably would resist outside assistance, even at the risk of putting their own citizens at risk and requiring the U.S. to improve its medical intelligence collection to protect its own and allied forces.[27] Some repressive regimes hit by SARS are likely to employ brutal tactics to quarantine and isolate people, possibly sowing division among outside countries and multilateral organizations over how to respond to apparent human rights violations. The worst case is a full resurgence of SARS could come back in the places it hit before—such as China, Taiwan, Canada, and Singapore—or hit harder in other well-connected places like the United States, Japan, Europe, India, or Brazil. Even if the number of infected persons were not significantly greater, the resurgence of the disease in globally linked countries probably would generate a significant impact again. The return of SARS to Asia is likely to cause somewhat less disruption the second time as citizens learn to live with the disease, but more multinational companies probably would reduce their exposure in the region if they concluded that SARS posed a long-term health challenge. Bigger outbreaks in Europe or the United States would hit a whole new set of business and government players, potentially doing serious damage to trade and growth. References1. ^1 2 3 4 5 6 7 {{citation | title = National Intelligence Estimate 99-17D: The Global Infectious Disease Threat and Its Implications for the United States | date = January 2000 | url = http://www.dni.gov/files/documents/infectiousdiseases_2000.pdf}} {{U.S. biological defense}}2. ^{{citation | title = Intelligence Community Assessment 2002-04D: The Next Wave of HIV AIDS | date = July 2002 | url = http://www.dni.gov/files/documents/Special%20Report_The%20Next%20Wave%20of%20HIV_AIDS.pdf}} 3. ^{{citation | title = Intelligence Community Assessment 2003-09 SARS Down but Still a Threat | date = August 2003 | url = http://www.dni.gov/files/documents/Special%20Report_SARS%20Down%20But%20Still%20a%20Threat.pdf}} 4. ^1 {{citation | title = National Intelligence Estimate 99-17D: The Global Infectious Disease Threat and Its Implications for the United States | date = January 2000 | url = http://www.fas.org/irp/threat/nie99-17d.htm | chapter = Impact within the United States}} 5. ^{{citation | journal = Emerging Infectious Diseases | title = Conference on Nosocomial and Healthcare-Associated Infections | editor = Solomon, Steven L. | url = http://www.medscape.com/viewarticle/414380 | doi = 10.3201/eid0702.010201 | year = 2001 | volume=7 | pages=169}} 6. ^{{citation | title = Meningococcal disease in the African Meningitis Belt, epidemic season 2006 | date = 21 March 2006 | author = World Health Organization, Epidemic and Pandemic Alert and Response (EPR) | url = http://www.who.int/csr/don/2006_03_21/en/index.html}} 7. ^1 2 3 4 5 {{citation | title = National Intelligence Estimate 99-17D: The Global Infectious Disease Threat and Its Implications for the United States | date = January 2000 | url = http://www.fas.org/irp/threat/nie99-17d.htm | chapter = Former Soviet Union (FSU) and Eastern Europe}} 8. ^1 2 3 4 {{citation | title = National Intelligence Estimate 99-17D: The Global Infectious Disease Threat and Its Implications for the United States | date = January 2000 | url = http://www.fas.org/irp/threat/nie99-17d.htm | chapter = Latin America}} 9. ^{{citation | title = Emerging Infectious Diseases: A CDC Perspective | author = Hughes, JM | journal = Emerging Infectious Diseases | volume = 7 | issue = 3, Supplement | date = June 2001 | doi = 10.3201/eid0707.017702 | url = https://www.cdc.gov/ncidod/eid/vol7no3_supp/hughes.htm | pages=494–495}} 10. ^{{citation | last1 = Bartoloni| first1=A | title = Increasing resistance in commensal Escherichia coli, Bolivia and Peru | journal = Emerging Infectious Diseases | date = February 2008 | pmid = 18258137 | doi = 10.3201/eid1402.070138 |display-authors=etal | volume=14 | pages=338–40 | pmc=2600201}} 11. ^1 {{citation | title = National Intelligence Estimate 99-17D: The Global Infectious Disease Threat and Its Implications for the United States | date = January 2000 | url = http://www.fas.org/irp/threat/nie99-17d.htm | chapter = The Middle East and North Africa region}} 12. ^1 2 {{citation | title = National Intelligence Estimate 99-17D: The Global Infectious Disease Threat and Its Implications for the United States | date = January 2000 | url = http://www.fas.org/irp/threat/nie99-17d.htm | chapter = Western Europe}} 13. ^{{citation|title=HIV testing policies and HIV surveillance among tuberculosis (TB) patients in Europe. |last1=Hamers |first1=FF, |last2=Infuso |first2=A. |conference=Int Conf AIDS |date=July 11–16, 2004 |url=http://gateway.nlm.nih.gov/MeetingAbstracts/102279882.htm }}{{dead link|date=June 2016|bot=medic}}{{cbignore|bot=medic}} 14. ^1 2 {{citation | title = National Intelligence Estimate 99-17D: The Global Infectious Disease Threat and Its Implications for the United States | date = January 2000 | url = http://www.fas.org/irp/threat/nie99-17d.htm | chapter = Response Capacity}} 15. ^{{citation | author = Aparna, Meduri | title = Product Patent Protection—India's Interest | date = December 2005 | ssrn = 902101 }} 16. ^{{citation | author =Fidler DP | title = Influenza virus samples, international law, and global health diplomacy | journal = Emerging Infectious Diseases | date = January 2008 | url = https://www.cdc.gov/EID/content/14/1/88.htm | pmid = 18258086 | doi = 10.3201/eid1401.070700 | volume=14 | pages=88–94 | pmc=2600156}} 17. ^1 {{citation | title = National Intelligence Estimate 99-17D: The Global Infectious Disease Threat and Its Implications for the United States | date = January 2000 | url = http://www.fas.org/irp/threat/nie99-17d.htm | chapter = Alternative Scenarios}} 18. ^{{Citation | title = The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment—Workshop Summary | year = 2003 | author = Board of Global Health, Institute of Medicine | chapter = 6, Emerging Tools and Technology for Countering Resistance | publisher = National Academies Press | url = http://books.nap.edu/openbook.php?record_id=10651&page=159}} 19. ^{{citation | title = National Intelligence Estimate 99-17D: The Global Infectious Disease Threat and Its Implications for the United States | date = January 2000 | url = http://www.fas.org/irp/threat/nie99-17d.htm | chapter = Economic, Social, and Political Impact}} 20. ^{{citation | author = Bell DM for the World Health Organization Working Group on Prevention of International and Community Transmission of SARS | title = Public health interventions and SARS spread | date=November 2004 | journal = Emerging Infectious Diseases | url =https://www.cdc.gov/ncidod/EID/vol10no11/04-0729.htm }} 21. ^{{citation |journal = Emerging Infectious Diseases |url = http://www.mt-archive.info/MTS-2005-Mawudeku.pdf |format=PDF|author = Mawudeku, A. |author2 = Blench, M. |title=Global Public Health Intelligence Network, |year = 2005}} 22. ^{{citation | url = http://www.medscape.com/viewarticle/467371 | last1 = Heymann | first1 = DL | last2 = Rodier | first2 =G | title = Global Surveillance, National Surveillance, and SARS | journal = Emerging Infectious Diseases | date = February 10, 2004 | pmid = 15040346 | doi=10.3201/eid1002.031038 | volume=10 | pages=173–5 | pmc=3322938}} 23. ^Heymann2004 24. ^"Mawadeku and Blench" 25. ^{{Citation |author = Monaghan, Karen |work = National Intelligence Council |title = SARS: Down But Still a Threat |id = ICA 2003-09 |date = August 2003 |url = http://dni.gov/nic/PDF_GIF_otherprod/sarsthreat/56797book.pdf |format = PDF |access-date = 2013-06-06 |archive-url = https://web.archive.org/web/20120609093014/http://www.dni.gov/nic/PDF_GIF_otherprod/sarsthreat/56797book.pdf |archive-date = 2012-06-09 |dead-url = yes |df = }} 26. ^{{citation|title=Hospital Infection Control Guidance for Severe Acute Respiratory Syndrome (SARS) |date=24 April 2003 |author=World Health Organization, Epidemic and Pandemic Alert and Response (EPR) |url=http://www.who.int/csr/sars/infectioncontrol/en/index.html |deadurl=yes |archiveurl=https://web.archive.org/web/20080523153309/http://www.who.int/csr/sars/infectioncontrol/en/index.html |archivedate=May 23, 2008 }} 27. ^{{citation | title = War on Severe Acute Respiratory Syndrome: United States Forces Korea's Campaign Plan | journal = Military Medicine | date = February 2006 | author = Casey, John J III | url = http://findarticles.com/p/articles/mi_qa3912/is_200602/ai_n16087443|display-authors=etal}} 1 : Intelligence reports |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。